Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN
FORT Study did not achieve its primary or secondary endpoints Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO , Aug. 22, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the Phase 3 FORT Study evaluating the safety and efficacy of
View HTML
Toggle Summary Retrophin Reports Second Quarter 2019 Financial Results
Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Commercial launch for THIOLA ® EC underway following FDA -approval for the treatment of cystinuria Second quarter revenues increased eight percent to $45 million SAN DIEGO , Aug.
View HTML
Toggle Summary Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference
SAN DIEGO , July 31, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube , Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Wednesday, August 7, 2019 at 8:30 a.m. ET .
View HTML
Toggle Summary Retrophin to Report Second Quarter 2019 Financial Results
SAN DIEGO , July 23, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
 Enteric-coated formulation offers flexible dosing options, including administration with or without food THIOLA EC expected to be available to patients next month SAN DIEGO , June 28, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S.
View HTML
Toggle Summary Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome
SAN DIEGO , June 18, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and patient
View HTML
Toggle Summary Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO , May 30, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in June: Jefferies 2019 Global Healthcare Conference Date: Tuesday, June 4, 2019 Time: 10:30 a.m.
View HTML
Toggle Summary NORD Launches New Program Aimed at Providing Caregivers with Relief
Grant program established with gift from Retrophin Washington, DC and San Diego, May 20, 2019 --The National Organization for Rare Disorders (NORD) Ⓡ , the leading independent nonprofit organization representing the 25-30 million Americans living with rare diseases, has launched the Rare Caregiver
View HTML
Toggle Summary Retrophin Appoints Sandra E. Poole to Board of Directors
Ms. Poole brings more than 25 years of biopharmaceutical product development and manufacturing experience to Retrophin SAN DIEGO , May 13, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Sandra E. Poole to the Company's Board of Directors, effective
View HTML
Toggle Summary Retrophin Reports First Quarter 2019 Financial Results
Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Enrollment ongoing in Phase 3 clinical trials of sparsentan for patients with rare nephropathies FSGS and IgAN Continued quarter over quarter growth in net product sales SAN DIEGO , May 07, 2019 (GLOBE NEWSWIRE) --
View HTML